Life Without Limitations





ÖSSUR INVESTOR MEETING Q1 2010

27 April 2010



Össur 2010 1 Copyright Ossur

Life Without Limitations





ÖSSUR HF.
JÓN SIGURÐSSON
President & CEO



ÖSSUR HIGHLIGHTS Q1 2010



Sales

USD 86 m

Strong Sales Growth

- Sales growth in B&S in Americas
- Continued strong growth in Prosthetics
- Overall sales growth 12%, 8% in LCY

Operations

EBITDA USD 18 m

Profitable Operations

- Gross profit margin 63%
- EBITDA 21%


Highlights

Key Highlights

- Successful product launches 12 new products
- US Healthcare reforms expected to materialize in 2013-2014

AMERICAS Q1 2010 - GOOD PERFORMANCE





Americas 48% of total sales

- Sales growth 15%
- Continued prosthetics growth
 - → RHEO strong contributor
- Growing in B&S sales
 - → Positive results from changes made
 - Further opportunities through regional specific strategy

Note: All growth numbers in local currency

EMEA Q1 2010 – SLOW QUARTER





EMEA 48% of total sales

- Sales in EMEA were flat
- Prosthetics growing
- Sales of B&S declined, affecting overall performance of EMEA
- Compression therapy 2% decline

Note: All growth numbers in local currency

ASIA Q1 2010 – EXCELLENT PERFORMANCE





Asia 4% of total sales


- Sales growth 20%
- Building up solid platform for future growth

Note: All growth numbers in local currency

U.S. HEALTHCARE REFORM



** Most significant healthcare reform since 1965, highly controversial



B&S PRODUCT PIPELINE DELIVERING



Life Without Limitations

Rebound Walker

Innovator DLX

Miami Lumbar Rigid lumbar belt Miami Lumbar TLSO ReSolve Halo Vest Miami J Advanced*













January

February

March

PROSTHETIC PRODUCT PIPELINE REMAINS STRONG



Life Without Limitations

Iceross Comfort Cushion Iceross Dermo Cushion Iceross Synergy
Cushion

Flex-Foot Balance

Total Knee 1100 Total Knee 2100













January

February

March

Life Without Limitations





FINANCIALS Q1 2010 HJÖRLEIFUR PÁLSSON *CFO*



FINANCIAL HIGHLIGHTS Q1 2010





- Strong overall sales growth
- Good profits
- Healthy balance sheet

INCOME STATEMENTS Q1 2010




Income Statements (USD millions)	Q1 2010	% of sales	Q1 2009	% of sales	Change	% change
Net sales	86.5	100.0%	77.2	100.0%	9.3	12.0%
Gross profit	54.1	62.6%	47.0	60.9%	7.1	15.0%
Operating expenses	-39.9	-46.2%	-39.2	-50.8%	-0.8	2.0%
Profit from operations	14.1	16.4%	7.8	10.2%	6.3	80.2%
Net profit	9.7	11.2%	7.6	9.8%	2.1	28.0%
ЕВІТОА	17.8	20.6%	12.9	16.7%	5.0	38.6%
EBITDA adjusted*	16.6	19.2%	13.6	17.6%	3.0	22.0%

^{•2009} Adjusted for one-time expenses: USD 0.7 million

^{•2010} Adjusted for one-time income: USD 1.2 million

SALES – STRONG GROWTH





- Overall 8% LCY sales growth
- B&S in Americas growing
- B&S in EMEA slight decline
- Continued success in Prosthetics

SALES GROWTH BY SEGMENTS Q1 2010



Sales by region / segments	Growth USD	Growth LCY	Organic growth LCY *
Americas	16%	15%	9%
EMEA	7%	0%	0%
Asia	29%	20%	20%
Total	12%	8%	5%
Prosthetics	15%	11%	11%
Bracing and supports	11%	6%	1%
Compression therapy	4%	-2%	-2%
Other products	0%	-7%	3%
Total	12%	8%	5%

^{*} Excluding acquired entities

GROSS PROFIT – SLIGHT INCREASE IN EFFICIENCY








OPERATING EXPENSES – STABLE IN REAL TERMS






- Marginal increase in operating expenses
- S&M investment in direct sales force
- R&D emphasis on product pipeline
- G&A similar levels
- Opportunities to benefit from economics of scale going forward

NET PROFIT - IS INCREASING






- Net profit up by USD 2.1 million, increasing 28%
- Driving profits up:
 - Increased efficiency
 - Favorable one time items
 - Lower amortizations
 - Acquired/sold entities
 - Slightly offset by negative exchange rate difference
- Net profit 9.7 million, 11% of sales

EBITDA MARGIN 19%








CASH FLOW - SEASONAL FLUCTUATIONS



NET CASH PROVIDED BY OPERATING ACTIVITIES



- Net cash from operations USD 8.3 million
- Prepayments USD 7.4 million
 - Prepayment USD 5 million
 - Prepayment USD 2.4 million proceeds from sale of fixed assets
- Net change in cash negative USD 6.1 million

CAPEX – WITHIN BENCHMARK







BALANCE SHEETS 31 MARCH 2010



USD '000	31. Mar '10	31. Dec '09
030 000	Ji. Wai 10	31. Dec 09
Non current assets	435,022	448,446
Current assets	171,410	179,771
Total assets	606,432	628,217
Stockholders' equity	312,457	312,223
Non current liabilities	227,590	237,045
Current liabilities	66,385	78,949
Total equity and liabilities	606,432	628,217
Current ratio	2.6	2.3
Equity ratio	52%	50%
Net interest bearing debt / EBITDA	2.0	2.4

- Long term debt maturity profile 2010 - 2015
- Net debt/EBITDA 2.0x
- Equity ratio 52%

FINANCIAL HIGHLIGHTS Q1 2010





- Strong overall sales growth
- Good profits
- Healthy balance sheet



WE IMPROVE PEOPLE'S MOBILITY



Listed on NASDAQ OMX Copenhagen

www.ossur.com

ÖSSUR

Life Without Limitations*